Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 16, Issue 3, 2009, Pages 168-177

  Friedrich Rust, M ^a   Theobald, J ^b   Zeuzem, S ^a   Bojunga, J ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Chronic hepatitis C; Echogenicity; Interferon; Power Doppler; Sonography; Thyroid dysfunction

Indexed keywords

LIOTHYRONINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNITY; DOPPLER FLOWMETRY; ECHOGRAPHY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; THYROID DISEASE; THYROID FUNCTION;

ADULT; AGED; ANTIVIRAL AGENTS; AUTOIMMUNITY; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RISK FACTORS; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID GLAND; YOUNG ADULT;

EID: 60349119647     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01059.x     Document Type: Article

References (35)

1. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
3. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
4. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003 124 : 1711 1719.
5. Preziati D, La Rosa L, Covini G et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995 132 : 587 593.
6. Roti E, Minelli R, Giuberti T et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996 101 : 482 487.
7. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006 43 : 661 672.
8. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003 13 : 547 551.
9. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab 2004 89 : 3656 3661.
10. Tran HA, Attia JR, Jones TL, Batey RG. Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. J Gastroenterol Hepatol 2007 22 : 472 476.
11. Carella C, Mazziotti G, Morisco F et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol 2002 146 : 743 749.
12. Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid 2007 17 : 223 228.
13. Schiemann U, Walli R, Schmidt F, Bogner J, Gross M. Thyroid hypoechogenicity in patients with chronic hepatitis receiving interferon-alpha therapy: evaluation by standardized grey scale ultrasonography. Eur J Med Res 2002 7 : 271 277.
14. Bogazzi F, Bartalena L, Brogioni S et al. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow doppler sonography. Eur J Endocrinol 1999 140 : 452 456.
15. Hollowell JG, Staehling NW, Flanders WD et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002 87 : 489 499.
16. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 1994 89 : 399 403.
17. Martocchia A, Labbadia G, Paoletti V et al. Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro Endocrinol Lett 2001 22 : 49 52.
18. Carella C, Mazziotti G, Morisco F et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001 86 : 1925 1929.
19. Baudin E, Marcellin P, Pouteau M et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol (Oxf) 1993 39 : 657 661.
20. Davies TF, Ando T, Lin RY, Tomer Y, Latif R Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 2005 115 : 1972 1983.
21. Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) 2002 56 : 793 798.
22. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992 102 : 2155 2160.
23. Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004 3 : 199 210.
24. Volpe R Etiology, pathogenesis, and clinical aspects of thyroiditis. Pathol Annu 1978 13 (Pt 2 399 413.
25. Weetman AP, Smallridge RC, Nutman TB, Burman KD. Persistent thyroid autoimmunity after subacute thyroiditis. J Clin Lab Immunol 1987 23 : 1 6.
26. Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996 25 : 283 291.
27. Imagawa A, Itoh N, Hanafusa T et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995 80 : 922 926.
28. Rodriguez-Torres M, Rios-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuetara AM, Jimenez-Rivera J. Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol 2008 7 : 72 77.
29. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997 7 : 891 896.
30. Nelson DR, Marousis CG, Davis GL et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997 158 : 1473 1481.
31. Hsieh MC, Yu ML, Chuang WL et al. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000 142 : 431 437.
32. Zusinaite E, Metskula K, Salupere R. Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia. World J Gastroenterol 2005 11 : 488 491.
33. Kryczka W, Brojer E, Kowalska A, Zarebska-Michaluk D. Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Med Sci Monit 2001 7 (Suppl. 1 221 225.
34. Ansar AS, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 1985 121 : 531 551.
35. Muratori L, Bogdanos DP, Muratori P et al. Susceptibility to thyroid disorders in hepatitis C. Clin Gastroenterol Hepatol 2005 3 : 595 603.